World & BusinessAdarx Pharmaceuticals raises $446.3 million in upsized IPO
The late-stage gene therapy developer priced its initial public offering at the top of its marketed range, Bloomberg reports.
TLDR
Bloomberg reports that Adarx Pharmaceuticals raised $446.3 million in an upsized IPO priced at the top of its marketed range. The company is a late-stage developer of gene therapies.
Adarx Pharmaceuticals raises $446.3 million in upsized IPO
The late-stage gene therapy developer priced its initial public offering at the top of its marketed range, Bloomberg reports.
TLDR
Bloomberg reports that Adarx Pharmaceuticals raised $446.3 million in an upsized IPO priced at the top of its marketed range. The company is a late-stage developer of gene therapies.